[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Singaram et al., 2023 - Google Patents

Targeting lipid–protein interaction to treat Syk-mediated acute myeloid leukemia

Singaram et al., 2023

View PDF
Document ID
6524058669096070296
Author
Singaram I
Sharma A
Pant S
Lihan M
Park M
Pergande M
Buwaneka P
Hu Y
Mahmud N
Kim Y
Cologna S
Gevorgyan V
Khan I
Tajkhorshid E
Cho W
Publication year
Publication venue
Nature chemical biology

External Links

Snippet

Membrane lipids control the cellular activity of kinases containing the Src homology 2 (SH2) domain through direct lipid–SH2 domain interactions. Here we report development of new nonlipidic small molecule inhibitors of the lipid–SH2 domain interaction that block the …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins

Similar Documents

Publication Publication Date Title
Guo et al. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Ferguson et al. Discovery of a selective inhibitor of doublecortin like kinase 1
Chen et al. Mutation-induced impacts on the switch transformations of the GDP-and GTP-bound K-ras: Insights from multiple replica Gaussian accelerated molecular dynamics and free energy analysis
Ayaz et al. Structural mechanism of a drug-binding process involving a large conformational change of the protein target
Spyrakis et al. The roles of water in the protein matrix: a largely untapped resource for drug discovery
Wang et al. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer
Singaram et al. Targeting lipid–protein interaction to treat Syk-mediated acute myeloid leukemia
Ball et al. An isothermal shift assay for proteome scale drug-target identification
McMillin et al. Structural basis of M3 muscarinic receptor dimer/oligomer formation
Okuzumi et al. Inhibitor hijacking of Akt activation
Zhou et al. KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non–small cell lung cancer
Wang et al. A dynamic charge-charge interaction modulates PP2A: B56 substrate recruitment
Lu et al. Designed covalent allosteric modulators: an emerging paradigm in drug discovery
Kok et al. Discovery of small-molecule enzyme activators by activity-based protein profiling
Kaneshige et al. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
Boulton et al. Mechanism of selective enzyme inhibition through uncompetitive regulation of an allosteric agonist
Feng et al. K-RasG12D has a potential allosteric small molecule binding site
Lee et al. Structure-based discovery of novel small molecule Wnt signaling inhibitors by targeting the cysteine-rich domain of frizzled
Yan et al. Structures of AMP-activated protein kinase bound to novel pharmacological activators in phosphorylated, non-phosphorylated, and nucleotide-free states
Hauseman et al. Structure of the MRAS–SHOC2–PP1C phosphatase complex
Zech et al. Novel small molecule inhibitors of choline kinase identified by fragment-based drug discovery
Xu et al. Precision therapeutic targeting of human cancer cell motility
Cheeseman et al. Exploiting protein conformational change to optimize adenosine-derived inhibitors of HSP70
Sheng et al. Lipids regulate Lck protein activity through their interactions with the Lck Src homology 2 domain
Granovsky et al. Raf kinase inhibitory protein function is regulated via a flexible pocket and novel phosphorylation-dependent mechanism